Note 16 - Fair Value Disclosures (Tables)

6 Months Ended

Jun. 30, 2020

Notes Tables

Fair Value, by Balance Sheet Grouping [Table Text Block]

			Fair Value Measured at Reporting Date Using
	Carrying Amount		Level 1		Level 2		Level 3		Fair Value
At June 30, 2020:
Cash and cash equivalents	$	8,440	$	-	$	8,440	$	-	$	8,440
Other receivables	$	349,003	$	-	$	-	$	349,003	$	349,003
Note receivable - related party	$	44,859	$	-	$	-	$	44,859	$	44,859
Advances to CEN Biotech Ukraine, LLC - related party	$	1,065,328	$	-	$	-	$	1,065,328	$	1,065,328
Loans payable	$	10,107,513	$	-	$	-	$	10,107,513	$	10,107,513
Loans payable – related parties	$	1,360,845	$	-	$	-	$	-	$	-
Patent acquisition liability	$	720,000	$	-	$	-	$	720,000	$	720,000
Convertible notes payable	$	6,434,445	$	-	$	-	$	7,283,393	$	7,283,393
Convertible notes payable – related parties	$	2,558,681	$	-	$	-	$	-	$	-

	Carrying Amount		Level 1		Level 2		Level 3		Fair Value
At December 31, 2019:
Cash and cash equivalents	$	3,757	$	-	$	3,757	$	-	$	3,757
Other receivables	$	424,110	$	-	$	-	$	424,110	$	424,110
Note receivable - related party	$	44,859	$	-	$	-	$	44,859	$	44,859
Advances to CEN Biotech Ukraine, LLC - related party	$	1,065,328	$	-	$	-	$	1,065,328	$	1,065,328
Loans payable	$	10,121,411	$	-	$	-	$	10,121,411	$	10,121,411
Loans payable – related parties	$	1,362,600	$	-	$	-	$	-	$	-
Patent acquisition liability	$	720,000	$	-	$	-	$	720,000	$	720,000
Convertible notes payable	$	6,224,325	$	-	$	-	$	6,918,486	$	6,918,486
Convertible notes payable – related parties	$	2,558,681	$	-	$	-	$	-	$	-